 Aptinyx Inc NASDAQ: APTX shares are plunging after results from a Phase 2b study of NYX-2925 in patients with painful diabetic peripheral neuropathy DPN. NYX-2925 did not achieve statistically significant separation from placebo on the studys primary endpoint, which. 